[vc_row][vc_column][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]£150,000 contract with Philip Morris Products, SA helps development of Reduced Risk Products*
Edinburgh; 18th February 2016; Arrayjet, the Scottish-based microarray instrumentation company, has won a £150,000 contract with Neuchâtel, Switzerland-headquartered, Philip Morris Products, SA (PMP), a wholly-owned subsidiary of Philip Morris International, Inc. (PMI), the world’s leading tobacco company.
PMI is working on an unparalleled program to develop Reduced Risk Products* (RRPs) with Arrayjet’s support – products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes.
Arrayjet is providing the microarray printing technology through its Marathon Argus printer, enabling PMP to produce exceptional precision and quality for the vast analysis and data for its research, providing full laboratory support to PMP’s existing Zeptosens Reverse phase protein array (RPPA) platform required for biomarker identification.
RRPs are in various stages of development and commercialization. PMP is carrying out extensive and rigorous scientific studies in its quest to develop innovative products that have the potential to reduce disease risk when compared to cigarette smoking.
Iain McWilliam, CEO, Arrayjet comments;
“PMI’s goal is to provide potentially reduced risk alternatives to smokers who would otherwise continue smoking cigarettes. The company is at the global forefront of this initiative and its scientific research and development program demonstrates its commitment to stringent scientific and global corporate and social responsibility practices. Arrayjet is delighted to provide the means to support this with our microarray printing technology helping to assist its scientific laboratory work.”
Dr. Ashraf Elamin, Manager Proteomics at Philip Morris Products said;
“Arrayjet’s Marathon Argus was selected to support and integrate with our Zeptosens RPPA microarray platform and this had helped produce faster results for both in vivo and in vitro studies. We increased the printing of high throughput of sample analysis whilst significantly optimising quality. We’re delighted with this ability to scale up our microarray printing capacity.”
This contract with Arrayjet underlines the growing international appeal of the Midlothian company having already secured overseas contracts this year in the US, Puerto Rico, Australia and China, demonstrating a strong demand for its microarray printer services across the life sciences and biomedical research industries.
Mike Rutterford, from the Scottish-based Archangels business angel syndicate who provide financial backing and support to Arrayjet comments;
“Attracting global players like Philip Morris underlines the increasingly important role Arrayjet is playing in medical and pharmaceutical research laboratories across the world. This is a significant contract for Arrayjet to be working with a strong consumer brand, but one which takes it’s a strong ethical and scientific approach to its future product development.”
* Reduced Risk Products (“RRPs”) is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking combustible cigarettes. PMI’s RRPs are in various stages of development, and we are conducting extensive and rigorous scientific studies to determine whether we can support claims for such products of reduced exposure to harmful and potentially harmful constituents in smoke, and ultimately claims of reduced disease risk, when compared to smoking combustible cigarettes. Before making any such claims, we will rigorously evaluate the full set of data from the relevant scientific studies to determine whether they substantiate reduced exposure or risk. Any such claims may also be subject to government review and approval, as is the case in the USA today.